ReviewPharmacological reviews2026

miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response.

Esmerina Tili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.